Drug Type Small molecule drug |
Synonyms Azor, Ol-Vamlo, Olmersartan medoxomil/amlodipine besilate + [6] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (26 Sep 2007), |
Regulation- |
Molecular FormulaC29H30N6O6 |
InChIKeyUQGKUQLKSCSZGY-UHFFFAOYSA-N |
CAS Registry144689-63-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Amlodipine Besylate/Olmesartan Medoxomil | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Essential Hypertension | CN | 12 Jul 2018 | |
Hypertension | US | 26 Sep 2007 |
Phase 4 | 600 | Olmesartan/Amlodipine 40/10 mg | flmjhprero(wdcvszltfz) = xepimqrazr bebiyextlp (nktgittdve ) View more | Positive | 01 Dec 2013 | ||
Perindopril/Amlodipine 8/10 mg | flmjhprero(wdcvszltfz) = mrybnglsow bebiyextlp (nktgittdve ) View more | ||||||
Not Applicable | 292 | trodaexvtk(ijwofwywri) = Incidence of study drug related adverse events was comparable in monotherapy and combination therapy group (2.77% vs 2.17%) fdgqupvmba (vhbdbiksgc ) | Positive | 01 Sep 2012 | |||
Phase 3 | 2,204 | Olmesartan(OLM) (Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg) | dtfevevqvr(wypvpoqhhs) = cxbynhynci cvjdqsqbwh (tlayciimfb, kcorbrbass - epplekirkd) View more | - | 22 Nov 2011 | ||
OLM 40+AML (OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5) | dtfevevqvr(wypvpoqhhs) = lwucciovjk cvjdqsqbwh (tlayciimfb, kzfyklmuao - pyipomcwmd) View more |